NCT03527823 is a clinical trial in Fertilization in Vitro, sponsored by Sebnem Alanya Tosun.

Who is sponsoring NCT03527823?

NCT03527823 is sponsored by Sebnem Alanya Tosun.

What condition does NCT03527823 study?

NCT03527823 studies Fertilization in Vitro.

Is NCT03527823 still recruiting?

NCT03527823 is currently completed. Last updated 22 June 2020.

Last reviewed 2020-06-22 · How we verify

NCT03527823

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Comparison of Granulosa Cell Apoptosis Rates With or Without Luteinizing Hormone Administration in Poor Responders.

Completed Last updated 22 June 2020

What this trial tests

trial in Fertilization in Vitro in 31 participants. Completed in 10 January 2019.

Timeline

17 October 2018

Primary endpoint
1 December 2018

10 January 2019

Quick facts

Lead sponsor	Sebnem Alanya Tosun
Status	Completed
Study type	OBSERVATIONAL
Enrollment	31
Start date	17 October 2018
Primary completion	1 December 2018
Estimated completion	10 January 2019
Sites	1 location across Turkey (Türkiye)

Conditions studied

Fertilization in Vitro — all drugs for Fertilization in Vitro →

Sponsor

Sebnem Alanya Tosun

Who can join

Adults 18 to 49, female only, with Fertilization in Vitro. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In Zeynep Kamil Women and Children's Education and Research Hospital which is a tertiary referral hospital, the investigators perform microdose flare-up gonadotropin-releasing hormone (GNRH) analogue or GNRH antagonist protocol to the poor responders. The investigators may or may not supplement luteinizing hormone (LH). Human chorionic gonadotropin (hCG) triggering is performed when at least 2 follicles diameter are above 17 mm and the serum estradiol level is above 500 pg / ml. 36 hours after hCG, ovarian aspiration is performed by the guidance of transvaginal ultrasound. Normally after oocyte separation process, the remaining follicle aspiration fluid is destroyed. n the present study, the follicle aspiration fluid is planned to be used with the patient's permission. The investigators are going to examine the granulosa cell apoptosis rate by using annexin-5 antibody in both groups 1 (LH added) and 2 (without LH). For this purpose, a total of 40 volunteer patients are planned to involve, the groups are designed as 20 LH added and 20 LH added women. In the present study, the investigators hypothesis that the rates of granulosa cell apoptosis in poor responders may be different between the group 1 (with LH) and group 2 (without LH), this will lead to IVF therapy in the near future.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effectiveness of hormone add-on strategies in ovarian stimulation for women with poor ovarian response: a systematic review and network meta-analysis of randomized controlled trials.
Etrusco A, Agrifoglio V, Castillo Farfán JC, Bernabeu Garcia A, et al · · 2025 · PMID 41136866 · DOI 10.1007/s10815-025-03633-z

Verify or expand the search:

Other recruiting trials for Fertilization in Vitro

Currently open trials in the same condition.

NCT06433518 — BEst Size for Ovulation Triggering in Poseidon 4 Patients (BEST 4 Study) · recruiting
NCT07175571 — SISTER: Sibling Oocyte Insemination With Frozen Sperm From Third Party Donors: Evaluation of Reproductive Techniques · NA · recruiting
NCT06410417 — Ejaculation Abstinence Time and Assisted Reproductive Technology Outcomes · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03527823 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sebnem Alanya Tosun
Last refreshed: 22 June 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03527823.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing